Eastman Kodak Co. announced Monday that it has receivednotification of allowance from the U.S. Patent and TrademarkOffice on its method of performing polymerase chain reaction(PCR) diagnosis.
The patent covers a containment device that allows clinicallaboratories to conduct PCR-based assays with a much lowerchance for contamination, according to Paul Allen, Kodak'smanager of media relations.
Kodak of Rochester, N.Y., became involved in PCR research in1986 through a collaboration with Cetus Inc. Hoffmann-LaRoche Inc. acquired the PCR technology from Cetus when thelatter merged with Chiron Corp. in 1991.
In early June, Kodak, Hoffmann-La Roche and Chiron settledthe ongoing dispute among the three regarding ownership andrights under PCR patents. Kodak (NYSE:EK) and its affiliatesreceived a non-exclusive royalty-bearing license withoutsublicensing rights limited to the in vitro human diagnosticsfield.
(c) 1997 American Health Consultants. All rights reserved.